Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 5 Jan 2024

Wu Qibiao, Ellis Haley, Siravegna Giulia, Michel Alexa G, Norden Bryanna L, Fece de la Cruz Ferran, Balasooriya Eranga Roshan, Zhen Yuanli, Silveira Vanessa S, Che Jianwe, Corcoran Ryan B, Bardeesy Nabeel

Abstract excerpt

PURPOSE: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible inhibitor, futibatinib. However, acquired resistance develops, limiting clinical benefit. Some mechanisms of resistance have been reported, including secondary FGFR2 kinase domain mutations. Here, we sought to establish the landscape of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Bile Ducts, Intrahepatic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 37843855
DOI: 10.1158/1078-0432.CCR-23-1317
PMCID: PMC10767308

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.PMID 37843855Read ↗

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read ↗

Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib.Semantic proximity Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Semantic proximity Read ↗

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.Semantic proximity Read ↗

Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.Semantic proximity Read ↗

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.Semantic proximity Read ↗

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.Semantic proximity Read ↗

The evolving role of futibatinib for advanced cholangiocarcinoma.Semantic proximity Read ↗

The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.Semantic proximity Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.